Eiger BioPharmaceuticals acquires exclusive license to lymphedema program from Stanford University

11 November 2015

Eiger BioPharmaceuticals has acquired an exclusive license to technology that could provide a potential therapeutic approach for treating lymphedema.

The technology targets the effects of leukotriene B4 (LTB4) to reverse structural tissue changes and improve lymphatic function, and provides a potential therapeutic approach to treat lymphedema. It was invented by Stanly Rockson, professor of cardiovascular medicine at Stanford University and director of the Stanford Center for Lymphatic and Venous Disorders.

The condition is a buildup of fluid in soft body tissues when the lymph system has been damaged or blocked, characterized by swelling due to abnormal transport of lyphatic fluid and thickening or hardening of skin in affected areas. There is currently no approved prescription therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK